NIPRIDE by Roche is 12. Approved for acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure and 2 more indications. First approved in 1974.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
NIPRIDE (sodium nitroprusside) is an intravenous vasodilator that produces nitric oxide to relax vascular smooth muscle, reducing both preload and afterload. It is indicated for acute heart failure management to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance, and mean arterial blood pressure. The drug acts within 1-2 minutes with effects dissipating rapidly upon infusion discontinuation.
As a legacy injectable approaching loss of exclusivity with moderate competitive pressure (score: 30), the brand team is likely focused on retention and cost-efficiency rather than expansion.
12.1 Mechanism of Action Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular…
Worked on NIPRIDE at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NIPRIDE offers limited growth opportunity but valuable experience in legacy product management, hospital-based selling, and complex safety monitoring (cyanide/thiocyanate toxicity). This role is best suited for professionals interested in niche acute care markets, cost-optimization strategies, or transition planning as the product approaches generic competition.